Irbesartan adverse effects

Irbesartan is a potent selective angiotensin II type 1 (ATi) receptor antagonist Its pharmacology is the same as that of other angiotensin II receptor antagonists (1). In the registration studies and other controlled trials adverse effects were not dose-related and not different from placebo. 

Angiotensin-II-receptor antagonists (ARBs) are approved for the treatment of hypertension. In addition, irbesartan and losartan are approved for diabetic nephropathy, losar-tan is approved for stroke prophylaxis, and valsartan is approved for heart failure patients who are intolerant of angiotensin-converting enzyme (ACE) inhibitors. The efficacy of ARBs in lowering blood pressure (BP) is comparable with that of other established antihypertensive drugs, with an adverse-effect profile similar to that of placebo. ARBs also are available as fixed-dose combinations with hydrochlorothiazide. 

---